Ion Exchange Q2 FY27: Loss of INR 828 Mn Reported

Revenue Stood at INR 6,747 Mn with Negative EBITDA of INR 848 Mn

Reader Takeaway: Legacy project cost adjustments and Middle East logistics delays triggered losses, though strong order inflows offer recovery potential.

What just happened

Ion Exchange India Ltd reported a consolidated net loss of INR 828 Mn for the quarter ending September 30, 2026, compared to a profit of INR 499 Mn in the year-ago period. Operating income declined by 8.1% year-on-year to INR 6,747 Mn. The primary driver for the financial dip was a revision in estimated costs to complete specific legacy projects within the Treatment Solutions segment, coupled with shipment delays caused by the ongoing crisis in the Middle East.

Why this matters

The negative bottom line marks a significant departure from the company's recent performance. The operating EBITDA margin dropped into negative territory at (12.57)%, reflecting the severity of the cost escalations and logistical hurdles. Shareholders are now looking toward the second half of the fiscal year to see if the company can offset these hits through the execution of its high-value order book.

Operational Performance Analysis

While the Treatment Solutions division faced immediate headwinds, other business units displayed signs of resilience:

• Industrial Products: Achieved strong growth, with turnover rising approximately 35% year-on-year.
• Specialty Chemicals: Reported sequential and year-on-year turnover improvements, though margins faced pressure from input cost inflation and expenses related to the new Roha facility.
• Lifecycle Services and Consumer Products: Both segments maintained positive momentum, with the latter continuing to deliver strong volume growth.

Risks to watch

Geopolitical instability in the Middle East remains a critical risk factor, as it impacts logistics for project exports. Furthermore, the ability of the management to pass through input cost increases in the Specialty Chemicals segment will be a key determinant of future margin recovery. Investors should monitor the conversion of the current INR 93,700 Mn bid pipeline into firm orders to sustain long-term growth.

What to track next

The focus shifts to the H2-FY27 execution schedule. Management has indicated that a strong order backlog and planned high-value contract deliveries are expected to stabilize the revenue base and improve the overall margin profile in the coming months.